Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of parkinsons disease

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Koppula, Sushruta ^a   Kumar, Hemant ^a   Kim, In Su ^a   Choi, Dong Kug ^a  

^a Konkuk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AGMATINE; AMINOETHYLBENZENESULFONYLFLUORIDE; AMINOGUANIDINE; APOCYNIN; DEXTROMETHORPHAN; DIPHENYLIODONIUM SALT; EBSELEN; ENZYME INHIBITOR; EPIGALLOCATECHIN; ESTRADIOL; GLYCERYL NONIVAMIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; INDUCIBLE NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITOR; MINOCYCLINE; N [2 (4 HYDROXYPHENYL)ETHYL] 2 (2,5 DIMETHOXYPHENYL) 3 (3 METHOXY 4 HYDROXYPHENYL)ACRYLAMIDE; NEUROPEPTIDE; NEUROPROTECTIVE AGENT; PHYCOCYANOBILIN; PYRUVIC ACID ETHYL ESTER; QUERCETIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE INHIBITOR; RESVERATROL; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SINOMENINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WOGONIN;

ANTIINFLAMMATORY ACTIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; HUMAN; NERVE CELL DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SCUTELLARIA BAICALENSIS; SIGNAL TRANSDUCTION; SPINAL CORD INJURY; ANIMAL; CHEMICAL MODEL; DISEASE MODEL; DOPAMINERGIC NERVE CELL; INFLAMMATION; MESENCEPHALON; METABOLISM; NERVE CELL; PATHOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; HUMANS; INFLAMMATION; MESENCEPHALON; MODELS, CHEMICAL; NADPH OXIDASE; NEURONS; NITRIC OXIDE SYNTHASE TYPE II; PARKINSON DISEASE; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84861015113     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/823902     Document Type: Review

References (146)

1. Reynolds A., Laurie C., Lee Mosley R., Gendelman H. E., Oxidative stress and the pathogenesis of neurodegenerative disorders International Review of Neurobiology 2007 82 297 325
2. Nunomura A., Perry G., Pappolla M. A., Wade R., Hirai K., Chiba S., Smith M. A., RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease Journal of Neuroscience 1999 19 6 1959 1964 (Pubitemid 29133374)
3. Barnham K. J., Masters C. L., Bush A. I., Neurodegenerative diseases and oxidatives stress Nature Reviews Drug Discovery 2004 3 3 205 214 (Pubitemid 38379987)
4. Emerit J., Edeas M., Bricaire F., Neurodegenerative diseases and oxidative stress Biomedicine and Pharmacotherapy 2004 58 1 39 46 (Pubitemid 38117047)
5. Inoue M., Sato E. F., Nishikawa M., Park A. M., Kira Y., Imada I., Utsumi K., Mitochondrial generation of reactive oxygen species and its role in aerobic life Current Medicinal Chemistry 2003 10 23 2495 2505 (Pubitemid 37460972)
6. Babior B. M., NADPH oxidase Current Opinion in Immunology 2004 16 1 42 47 (Pubitemid 38198116)
7. Griendling K. K., Sorescu D., Ushio-Fukai M., NAD(P)H oxidase: role in cardiovascular biology and disease Circulation Research 2000 86 5 494 501 (Pubitemid 30165039)
8. Groeger G., Quiney C., Cotter T. G., Hydrogen peroxide as a cell-survival signaling molecule Antioxidants and Redox Signaling 2009 11 11 2655 2671
9. Valko M., Leibfritz D., Moncol J., Cronin M. T. D., Mazur M., Telser J., Free radicals and antioxidants in normal physiological functions and human disease International Journal of Biochemistry and Cell Biology 2007 39 1 44 84 (Pubitemid 44566469)
10. Pelicano H., Carney D., Huang P., ROS stress in cancer cells and therapeutic implications Drug Resistance Updates 2004 7 2 97 110 (Pubitemid 38736063)
11. E. Thomas C., Kalyanaraman B., Oxygen Radicals and the Disease Process 1997 Hardwood Academic Publishers
12. Halliwell B., Gutteridge J. M. C., Role of free radicals and catalytic metal ions in human disease: an overview Methods in Enzymology 1990 186 1 85 (Pubitemid 20279941)
13. Wu D. C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S., NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease Proceedings of the National Academy of Sciences of the United States of America 2003 100 10 6145 6150 (Pubitemid 36576945)
14. Liberatore G. T., Jackson-Lewis V., Vukosavic S., Mandir A. S., Vila M., Mcauliffe W. G., Dawson V. L., Dawson T. M., Przedborski S., Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease Nature Medicine 1999 5 12 1403 1409
15. Hunot S., Boissire F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E. C., Nitric oxide synthase and neuronal vulnerability in Parkinson's disease Neuroscience 1996 72 2 355 363 (Pubitemid 26111202)
16. Przedborski S., Ischiropoulos H., Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson's disease Antioxidants and Redox Signaling 2005 7 5-6 685 693 (Pubitemid 40563207)
17. Schapira A. H. V., Pathogenesis of Parkinson's disease Bailliere's Clinical Neurology 1997 6 1 15 36 (Pubitemid 28007824)
18. Alam Z. I., Daniel S. E., Lees A. J., Marsden D. C., Jenner P., Halliwell B., A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease Journal of Neurochemistry 1997 69 3 1326 1329 (Pubitemid 27364859)
19. Schulz J. B., Beal M. F., Mitochondrial dysfunction in movement disorders Current Opinion in Neurology 1994 7 4 333 339 (Pubitemid 24243738)
20. Slivka A., Cohen G., Hydroxyl radical attack on dopamine Journal of Biological Chemistry 1985 260 29 15466 15472 (Pubitemid 16170079)
21. Greenamyre J. T., Hastings T. G., Parkinsonsdivergent causes convergent mechanisms Science 2004 304 5674 1120 1122
22. Ischiropoulos H., Beckman J. S., Oxidative stress and nitration in neurodegeneration: cause, effect, or association? Journal of Clinical Investigation 2003 111 2 163 169 (Pubitemid 36105911)
23. Jenner P., Oxidative stress in Parkinson's disease Annals of Neurology 2003 53, supplement 3 S26 S38
24. Kanthasamy A. G., Kitazawa M., Kanthasamy A., Anantharam V., Role of proteolytic activation of protein Kinase C in oxidative stress-induced apoptosis Antioxidants and Redox Signaling 2003 5 5 609 620 (Pubitemid 37315149)
25. Koutsilieri E., Scheller C., Grnblatt E., Nara K., Li J., Riederer P., Free radicals in Parkinson's disease Journal of Neurology 2002 249 2, supplement 2 II1 II5
26. Love R., Mitochondria back in the spotlight in Parkinson's disease Lancet Neurology 2004 3 6 326
27. Tikka T. M., Vartiainen N. E., Goldsteins G., Oja S. S., Andersen P. M., Marklund S. L., Koistinaho J., Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease Brain 2002 125 4 722 731 (Pubitemid 34279769)
28. Andersen J. K., Iron dysregulation and Parkinson's disease Journal of Alzheimer's Disease 2004 6 S47 S52
29. Mancuso C., Scapagnini G., Curr D., Giuffrida Stella A. M., De Marco C., Butterfield D. A., Calabrese V., Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders Frontiers in Bioscience 2007 12 3 1107 1123 (Pubitemid 46846882)
30. Mandel S., Maor G., Youdim M. B. H., Iron and -synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate Journal of Molecular Neuroscience 2004 24 3 401 416 (Pubitemid 41389377)
31. Youdim M. B. H., Stephenson G., Shachar D. B., Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28 Annals of the New York Academy of Sciences 2004 1012 306 325 (Pubitemid 38453534)
32. Venero J. L., Burguillos M. A., Brundin P., Joseph B., The executioners sing a new song: killer caspases activate microglia Cell Death and Differentiation 2011 18 11 1679 1691
33. Dickson D. W., Lee S. C., Mattiace L. A., Yen S. H., Brosnan C., Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease Glia 1993 7 1 75 83
34. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 1988 38 8 1285 1291
35. Raine C. S., Multiple sclerosis: immune system molecule expression in the central nervous system Journal of Neuropathology and Experimental Neurology 1994 53 4 328 337 (Pubitemid 24216030)
36. Rogers J., Luber-Narod J., Styren S. D., Civin W. H., Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease Neurobiology of Aging 1988 9 4 339 349 (Pubitemid 19262065)
37. Knott C., Stern G., Wilkin G. P., Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2 Molecular and Cellular Neuroscience 2000 16 6 724 739 (Pubitemid 32062060)
38. Choi D. K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D. C., Jackson-Lewis V., Vila M., Vonsattel J. P., Heinecke J. W., Przedborski S., Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice Journal of Neuroscience 2005 25 28 6594 6600 (Pubitemid 40995291)
39. Van Leyen K., Arai K., Jin G., Kenyon V., Gerstner B., Rosenberg P. A., Holman T. R., Lo E. H., Novel lipoxygenase inhibitors as neuroprotective reagents Journal of Neuroscience Research 2008 86 4 904 909 (Pubitemid 351357770)
40. Glass C. K., Saijo K., Winner B., Marchetto M. C., Gage F. H., Mechanisms Underlying Inflammation in Neurodegeneration Cell 2010 140 6 918 934
41. Ransohoff R. M., Perry V. H., Microglial physiology: unique stimuli, specialized responses Annual Review of Immunology 2009 27 119 145
42. Chen H., Nonsteroidal antiinflammatory drugs and the risk of Parkinsons disease Movement Disorder 2002 17 S143 S144
43. McGeer P. L., McGeer E. G., Inflammatory processes in amyotrophic lateral sclerosis Muscle and Nerve 2002 26 4 459 470
44. Babior B. M., NADPH oxidase: an update Blood 1999 93 5 1464 1476 (Pubitemid 29102471)
45. Sawada M., Imamura K., Nagatsu T., Role of cytokines in inflammatory process in Parkinson's disease Journal of Neural Transmission, Supplement 2006 70 373 381 (Pubitemid 44622226)
46. Serrano F., Kolluri N. S., Wientjes F. B., Card J. P., Klann E., NADPH oxidase immunoreactivity in the mouse brain Brain Research 2003 988 1-2 193 198 (Pubitemid 37289510)
47. Ushio-Fukai M., Localizing NADPH oxidase-derived ROS Science's STKE 2006 2006 349 re8
48. Infanger D. W., Sharma R. V., Davisson R. L., NADPH oxidases of the brain: distribution, regulation, and function Antioxidants and Redox Signaling 2006 8 9-10 1583 1596 (Pubitemid 44726333)
49. Tabner B. J., Turnbull S., El-Agnaf O., Allsop D., Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases Current Topics in Medicinal Chemistry 2001 1 6 507 517
50. Zhang W., Wang T., Pei Z., Miller D. S., Wu X., Block M. L., Wilson B., Zhang W., Zhou Y., Hong J. S., Zhang J., Aggregated -synuclein activates microglia: a process leading to disease progression in Parkinson's disease FASEB Journal 2005 19 6 533 542 (Pubitemid 40471244)
51. Thomas M. P., Chartrand K., Reynolds A., Vitvitsky V., Banerjee R., Gendelman H. E., Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease Journal of Neurochemistry 2007 100 2 503 519 (Pubitemid 46011009)
52. Tolando R., Jovanovi A., Brigelius-Flohé R., Ursini F., Maiorino M., Reactive oxygen species and proinflammatory cytokine signaling in endothelial cells: effect of selenium supplementation Free Radical Biology and Medicine 2000 28 6 979 986 (Pubitemid 30235172)
53. Sundaresan M., Yu Z. X., Ferrans V. J., Irani K., Finkel T., Requirement for generation of H 2 O 2 for platelet-derived growth factor signal transduction Science 1995 270 5234 296 299
54. Suzukawa K., Miura K., Mitsushita J., Resau J., Hirose K., Crystal R., Kamata T., Nerve growth factor-induced neuronal differentiation requires generation of Rac1-regulated reactive oxygen species Journal of Biological Chemistry 2000 275 18 13175 13178 (Pubitemid 30257368)
55. Gao H. M., Liu B., Hong J. S., Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons Journal of Neuroscience 2003 23 15 6181 6187 (Pubitemid 36875618)
56. Block M. L., Wu X., Pei Z., Li G., Wang T., Qin L., Wilson B., Yang J., Hong J. S., Veronesi B., Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase FASEB Journal 2004 18 13 1618 1620 (Pubitemid 39561652)
57. Qin L., Liu Y., Cooper C., Liu B., Wilson B., Hong J. S., Microglia enhance -amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species Journal of Neurochemistry 2002 83 4 973 983 (Pubitemid 35316048)
58. Wu X. F., Block M. L., Zhang W., Qin L., Wilson B., Zhang W. Q., Veronesi B., Hong J. S., The role of microglia in paraquat-induced dopaminergic neurotoxicity Antioxidants and Redox Signaling 2005 7 5-6 654 661 (Pubitemid 40563204)
59. Gao H. M., Hong J. S., Zhang W., Liu B., Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease Journal of Neuroscience 2003 23 4 1228 1236 (Pubitemid 36258901)
60. Green S. P., Cairns B., Rae J., Errett-Baroncini C., Hongo J. A. S., Erickson R. W., Curnutte J. T., Induction of gp91-phox, a component of the phagocyte NADPH oxidase, in microglial cells during central nervous system inflammation Journal of Cerebral Blood Flow and Metabolism 2001 21 4 374 384 (Pubitemid 32298884)
61. Anantharam V., Kaul S., Song C., Kanthasamy A., Kanthasamy A. G., Pharmacological inhibition of neuronal NADPH oxidase protects against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress and apoptosis in mesencephalic dopaminergic neuronal cells NeuroToxicology 2007 28 5 988 997 (Pubitemid 47519806)
62. Qin L., Liu Y., Wang T., Wei S. J., Block M. L., Wilson B., Liu B., Hong J. S., NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia Journal of Biological Chemistry 2004 279 2 1415 1421 (Pubitemid 38082669)
63. Huh S. H., Chung Y. C., Piao Y., Jin M. Y., Son H. J., Yoon N. S., Hong J. Y., Pak Y. K., Kim Y. S., Hong J. K., Hwang O., Jin B. K., Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease Journal of Immunology 2011 187 2 960 969
64. Wang Q., Tompkins K. D., Simonyi A., Korthuis R. J., Sun A. Y., Sun G. Y., Apocynin protects against global cerebral ischemia-reperfusion-induced oxidative stress and injury in the gerbil hippocampus Brain Research 2006 1090 1 182 189 (Pubitemid 43817927)
65. Lo W., Bravo T., Jadhav V., Titova E., Zhang J. H., Tang J., NADPH oxidase inhibition improves neurological outcomes in surgically-induced brain injury Neuroscience Letters 2007 414 3 228 232
66. Lull M. E., Levesque S., Surace M. J., Block M. L., Chronic apocynin treatment attenuates beta amyloid plaque size and microglial number in hAPP(751) SL mice PLoS One 2011 6 5, article e20153
67. Tang X. N., Cairns B., Cairns N., Yenari M. A., Apocynin improves outcome in experimental stroke with a narrow dose range Neuroscience 2008 154 2 556 562
68. Titova E., Ostrowski R. P., Sowers L. C., Zhang J. H., Tang J., Effects of apocynin and ethanol on intracerebral haemorrhage-induced brain injury in rats Clinical and Experimental Pharmacology and Physiology 2007 34 9 845 850 (Pubitemid 47083966)
69. Miller R. L., Sun G. Y., Sun A. Y., Cytotoxicity of paraquat in microglial cells: involvement of PKC -and ERK1/2-dependent NADPH oxidase Brain Research 2007 1167 1 129 139 (Pubitemid 47302435)
70. Qian L., Xu Z., Zhang W., Wilson B., Hong J. S., Flood P. M., Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase Journal of Neuroinflammation 2007 4, article no. 23
71. Ma L., Zhou J., Dopamine promotes the survival of embryonic striatal cells: involvement of superoxide and endogenous NADPH oxidase Neurochemical Research 2006 31 4 463 471 (Pubitemid 43873740)
72. Nikolova S., Lee Y. S., Lee Y. S., Kim J. A., Rac1-NADPH oxidase-regulated generation of reactive oxygen species mediates glutamate-induced apoptosis in SH-SY5Y human neuroblastoma cells Free Radical Research 2005 39 12 1295 1304 (Pubitemid 43023794)
73. Purisai M. G., McCormack A. L., Cumine S., Li J., Isla M. Z., Di Monte D. A., Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration Neurobiology of Disease 2007 25 2 392 400 (Pubitemid 46124019)
74. Yasuhara T., Shingo T., Kobayashi K., Takeuchi A., Yano A., Muraoka K., Matsui T., Miyoshi Y., Hamada H., Date I., Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease European Journal of Neuroscience 2004 19 6 1494 1504 (Pubitemid 38437912)
75. Hirsch E. C., Breidert T., Rousselet E., Hunot S., Hartmann A., Michel P. P., The role of glial reaction and inflammation in Parkinson's disease Annals of the New York Academy of Sciences 2003 991 214 228 (Pubitemid 36793816)
76. Gao H. M., Zhang F., Zhou H., Kam W., Wilson B., Hong J. -S., Neuroinflammation and -synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease Environmental Health Perspectives 2011 119 6 807 814
77. Liu Y., Qin L., Li G., Zhang W., An L., Liu B., Hong J. S., Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation Journal of Pharmacology and Experimental Therapeutics 2003 305 1 212 218 (Pubitemid 36373853)
78. Li G., Liu Y., Tzeng N. S., Cui G., Block M. L., Wilson B., Qin L., Wang T., Liu B., Liu J., Hong J. S., Protective effect of dextromethorphan against endotoxic shock in mice Biochemical Pharmacology 2005 69 2 233 240 (Pubitemid 41556569)
79. Zhang W., Wang T., Qin L., Gao H. M., Wilson B., Ali S. F., Zhang W., Hong J. S., Liu B., Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase The FASEB Journal 2004 18 3 589 591
80. Ramanathan M., Sivakumar S., Anandvijayakumar P. R., Saravanababu C., Pandian P. R., Neuroprotective evaluation of standardized extract of centella asciatica in monosodium glutamate treated rats Indian Journal of Experimental Biology 2007 45 5 425 431
81. Huo Y., Rangarajan P., Ling E. A., Dheen S. T., Dexamethasone inhibits the Nox-dependent ROS production via suppression of MKP-1-dependent MAPK pathways in activated microglia BMC Neuroscience 2011 12, article 49
82. Zhang W., Shin E. J., Wang T., Phil H. L., Pang H., Wie M. B., Kim W. K., Kim S. J., Huang W. H., Wang Y., Zhang W., Hong J. S., Kim H. C., 3-Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP-elicited damage both in vivo and in vitro FASEB Journal 2006 20 14 2496 2511 (Pubitemid 44953822)
83. Zhang F., Shi J. S., Zhou H., Wilson B., Hong J. S., Gao H. M., Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions Molecular Pharmacology 2010 78 3 466 477
84. Li R., Huang Y. G., Fang D., Le W. D., (-)-Epigallocatechin gallate inhibits lipopolysaccharide-induced microglial activation and protects against inflammation-mediated dopaminergic neuronal injury Journal of Neuroscience Research 2004 78 5 723 731 (Pubitemid 39657589)
85. Wang L., Xu S., Xu X., Chan P., (-)-epigallocatechin-3-gallate protects SH-SY5Y cells against 6-OHDA-induced cell death through stat3 activation Journal of Alzheimer's Disease 2009 17 2 295 304
86. Ruan H., Yang Y., Zhu X., Wang X., Chen R., Neuroprotective effects of ()-catechin against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity in mice Neuroscience Letters 2009 450 2 152 157
87. Arimura A., Perspectives on pituitary adenylate cyclase activating polypeptide (PACAP) in the neuroendocrine, endocrine, and nervous systems Japanese Journal of Physiology 1998 48 5 301 331 (Pubitemid 28566695)
88. Arimura A., Somogyvari-Vigh A., Weill C., Fiore R. C., Tatsuno I., Bay V., Brenneman D. E., PACAP functions as a neurotrophic factor Annals of the New York Academy of Sciences 1994 739 228 243
89. Kozicz T., Vigh S., Arimura A., Axon terminals containing PACAP- and VIP-immunoreactivity form synapses with CRF-immunoreactive neurons in the dorsolateral division of the bed nucleus of the stria terminalis in the rat Brain Research 1997 767 1 109 119 (Pubitemid 27428558)
90. Brenneman D. E., Hauser J. M., Spong C. Y., Phillips T. M., Chemokine release is associated with the protective action of PACAP-38 against HIV envelope protein neurotoxicity Neuropeptides 2002 36 4 271 280 (Pubitemid 35192189)
91. Uchida D., Arimura A., Somogyvri-Vigh A., Shioda S., Banks W. A., Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide Brain Research 1996 736 1-2 280 286 (Pubitemid 26356486)
92. Yang S., Yang J., Yang Z., Chen P., Fraser A., Zhang W., Pang H., Gao X., Wilson B., Hong J. S., Block M. L., Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress Journal of Pharmacology and Experimental Therapeutics 2006 319 2 595 603
93. Zhang Q. G., Raz L., Wang R., Han D., De Sevilla L., Yang F., Vadlamudi R. K., Brann D. W., Estrogen attenuates ischemic oxidative damage via an estrogen receptor -mediated inhibition of NADPH oxidase activation Journal of Neuroscience 2009 29 44 13823 13836
94. Dhandapani K. M., Brann D. W., Role of astrocytes in estrogen-mediated neuroprotection Experimental Gerontology 2007 42 1-2 70 75 (Pubitemid 44937829)
95. Prehn J. H. M., Bindokas V. P., Marcuccilli C. J., Krajewski S., Reed J. C., Miller R. J., Regulation of neuronal Bcl2 protein expression and calcium homeostasis by transforming growth factor type confers wide-ranging protection on rat hippocampal neurons Proceedings of the National Academy of Sciences of the United States of America 1994 91 26 12599 12603
96. Qian L., Flood P. M., Microglial cells and Parkinson's disease Immunologic Research 2008 41 3 155 164
97. Zhang D., Hu X., Wei S. J., Liu J., Gao H., Qian L., Wilson B., Liu G., Hong J. S., Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity Journal of Neuroinflammation 2008 5, article no. 21
98. Lanone S., Bloc S., Foresti R., Almolki A., Taillé C., Callebert J., Conti M., Goven D., Aubier M., Dureuil B., El-Benna J., Motterlini R., Boczkowski J., Bilirubin decreases nos2 expression via inhibition of NAD(P)H oxidase: implications for protection against endotoxic shock in rats FASEB Journal 2005 19 13 1890 1892 (Pubitemid 41598785)
99. Santiago M., Hernndez-Romero M. C., Machado A., Cano J., Zocor Forte (simvastatin) has a neuroprotective effect against LPS striatal dopaminergic terminals injury, whereas against MPP + does not European Journal of Pharmacology 2009 609 13 58 64
100. Nakamichi K., Saiki M., Kitani H., Kuboyama Y., Morimoto K., Takayama-Ito M., Kurane I., Suppressive effect of simvastatin on interferon- -induced expression of CC chemokine ligand 5 in microglia Neuroscience Letters 2006 407 3 205 210 (Pubitemid 44402874)
101. Cordle A., Landreth G., 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate -amyloid-induced microglial inflammatory responses Journal of Neuroscience 2005 25 2 299 307 (Pubitemid 40105600)
102. Yan J., Xu Y., Zhu C., Zhang L., Wu A., Yang Y., Xiong Z., Deng C., Huang X. -F., Yenari M. A., Yang Y. -G., Ying W., Wang Q., Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses PLoS One 2011 6 6, article 20945
103. Chen W., Pendyala S., Natarajan V., Garcia J. G. N., Jacobson J. R., Endothelial cell barrier protection by simvastatin: GTPase regulation and NADPH oxidase inhibition American Journal of Physiology, Lung Cellular and Molecular Physiology 2008 295 4 L575 L583
104. Thomas M., Le W. D., Jankovic J., Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease Clinical Neuropharmacology 2003 26 1 18 23 (Pubitemid 36184111)
105. Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D. K., Ischiropoulos H., Przedborski S., Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease Journal of Neuroscience 2002 22 5 1763 1771 (Pubitemid 35386294)
106. Choi S. H., Lee D. Y., Chung E. S., Hong Y. B., Kim S. U., Jin B. K., Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra in vivo Journal of Neurochemistry 2005 95 6 1755 1765 (Pubitemid 41804071)
107. Choi D. K., Koppula S., Choi M., Suk K., Recent developments in the inhibitors of neuroinflammation and neurodegeneration: inflammatory oxidative enzymes as a drug target Expert Opinion on Therapeutic Patents 2010 20 11 1531 1546
108. Page P., Orchard M., Fioraso L., Mottiromi B., Pyrazolo pyridine derivatives as NADPH oxidase inhibitors. US 20100048560, 2010
109. Page P., Orchard M., Fioraso L., Mottiromi B., Tetrahydroindole derivatives as NADPH oxidase inhibitors. EP2139472A1, 2010
110. L. Arbiser J., Use of Imipramine blue and analogs thereof in treating cancers. US20100160296, 2010
111. I. Onda K., Sato K., Moritomo F., Urano H., Sawada Y., Ishibashi Y., Nakanishi N., Yokoyama K., Furukawa K., Momose S., Quinolone derivatives. EP20080834496, 2010
112. S. Yamamoto M., U. Saneyoshi A., NADH/NADPH oxidase inhibitors. JP2009007256, 2009
113. Przedborski S., M. Dawson T., The role of nitric oxide in Parkinson's disease Methods in Molecular Medicine 2001 62 113 136
114. Dinerman J. L., Dawson T. M., Schell M. J., Snowman A., Snyder S. H., Endothelial nitric oxide synthase localized to hippocampal pyramidal cells: implications for synaptic plasticity Proceedings of the National Academy of Sciences of the United States of America 1994 91 10 4214 4218 (Pubitemid 24143403)
115. Murphy S., Production of nitric oxide by glial cells: regulation and potential roles in the CNS GLIA 2000 29 1 1 13 (Pubitemid 30031129)
116. Heneka M. T., Feinstein D. L., Expression and function of inducible nitric oxide synthase in neurons Journal of Neuroimmunology 2001 114 1-2 8 18 (Pubitemid 32184720)
117. Bal-Price A., Brown G. C., Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity Journal of Neuroscience 2001 21 17 6480 6491 (Pubitemid 32781092)
118. Bal-Price A., Matthias A., Brown G. C., Stimulation of the NADPH oxidase in activated rat microglia removes nitric oxide but induces peroxynitrite production Journal of Neurochemistry 2002 80 1 73 80 (Pubitemid 34614579)
119. Ye Y. Z., Strong M., Huang Z. Q., Beckman J. S., Antibodies that recognize nitrotyrosine Methods in Enzymology 1996 269 201 209 (Pubitemid 26295709)
120. Dexter D., Carter C., Agid F., Lipid peroxidation as cause of nigral cell death in Parkinson's disease Lancet 1986 2 8507 639 640 (Pubitemid 16055627)
121. Broom L., Marinova-Mutafchieva L., Sadeghian M., Davis J. B., Medhurst A. D., Dexter D. T., Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease Free Radical Biology and Medicine 2011 50 5 633 640
122. Gahm C., Holmin S., Wiklund P. N., Brundin L., Mathiesen T., Neuroprotection by selective inhibition of inducible nitric oxide synthase after experimental brain contusion Journal of Neurotrauma 2006 23 9 1343 1354 (Pubitemid 46489620)
123. Griffiths M. J. D., Messent M., MacAllister R. J., Evans T. W., Aminoguanidine selectively inhibits inducible nitric oxide synthase British Journal of Pharmacology 1993 110 3 963 968 (Pubitemid 24005226)
124. Sun M., Zhao Y., Gu Y., Xu C., Neuroprotective actions of aminoguanidine involve reduced the activation of calpain and caspase-3 in a rat model of stroke Neurochemistry International 2010 56 4 634 641
125. Wolff D. J., Lubeskie A., Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase Archives of Biochemistry and Biophysics 1995 316 1 290 301
126. Cash D., Beech J. S., Rayne R. C., Bath P. M. W., Meldrum B. S., Williams S. C. R., Neuroprotective effect of aminoguanidine on transient focal ischaemia in the rat brain Brain Research 2001 905 1-2 91 103 (Pubitemid 32553842)
127. Lu J., Moochhala S., Shirhan M., Ng K. C., Teo A. L., Tan M. H., Moore X. L., Wong M. C., Ling E. A., Neuroprotection by aminoguanidine after lateral fluid-percussive brain injury in rats: a combined magnetic resonance imaging, histopathologic and functional study Neuropharmacology 2003 44 2 253 263 (Pubitemid 36293265)
128. Cockroft K. M., Meistrell M., Zimmerman G. A., Risucci D., Bloom O., Cerami A., Tracey K. J., Cerebroprotective effects of aminoguanidine in a rodent model of stroke Stroke 1996 27 8 1393 1398 (Pubitemid 26286174)
129. Stevanovi I. D., Jovanovi M. D., oli M., Jelenkovi A., Mihajlovi R., Stojanovi I., Ninkovi M., The effect of aminoguanidine, an inducible nitric oxide synthase inhibitor, on ALCL 3 toxicity in the rat hippocampus Archives of Biological Sciences 2010 62 4 981 991
130. Zhang Z. J., Cheang L. C.V., Wang M. W., Lee S. M.-Y., Quercetin exerts a neuroprotective effect through inhibition of the iNOS/NO system and pro-inflammation gene expression in PC12 cells and in zebrafish International Journal of Molecular Medicine 2011 27 2 195 203
131. Lin Y. C., Uang H. W., Lin R. J., Chen I. J., Lo Y. C., Neuroprotective effects of glyceryl nonivamide against microglia-like cells and 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells Journal of Pharmacology and Experimental Therapeutics 2007 323 3 877 887
132. Kotil K., Kuscuoglu U., Kirali M., Uzun H., Aketin M., Bilge T., Investigation of the dose-dependent neuroprotective effects of agmatine in experimental spinal cord injury: a prospective randomized and placebo-control trial Journal of Neurosurgery: Spine 2006 4 5 392 399 (Pubitemid 47325446)
133. Condello S., Curro M., Ferlazzo N., Caccamo D., Satriano J., Ientile R., Agmatine effects on mitochondrial membrane potential andNF-kappaB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells Journal of Neurochemistry 2011 116 1 67 75
134. Kim H., Kim Y. S., Kim S. Y., Suk K., The plant flavonoid wogonin suppresses death of activated C6 rat glial cells by inhibiting nitric oxide production Neuroscience Letters 2001 309 1 67 71 (Pubitemid 32728261)
135. Chun W., Hee J. L., Kong P. J., Gun H. L., Cheong I. Y., Park H., Kim S. S., Synthetic wogonin derivatives suppress lipopolysaccharide-induced nitric oxide production and hydrogen peroxide-induced cytotoxicity Archives of Pharmacal Research 2005 28 2 216 219 (Pubitemid 43073675)
136. Hattori R., Inoue R., Sase K., Eizawa H., Kosuga K., Aoyama T., Masayasu H., Kawai C., Sasayama S., Yui Y., Preferential inhibition of inducible nitric oxide synthase by ebselen European Journal of Pharmacology, Molecular Pharmacology Section 1994 267 2 R1 R2
137. Moussaoui S., Obinu M. C., Daniel N., Reibaud M., Blanchard V., Imperato A., The antioxidant Ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease Experimental Neurology 2000 166 2 235 245
138. Dehmer T., Heneka M. T., Sastre M., Dichgans J., Schulz J. B., Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I B induction and block of NF B and iNOS activation Journal of Neurochemistry 2004 88 2 494 501 (Pubitemid 38084565)
139. Hunter R. L., Dragicevic N., Seifert K., Choi D. Y., Liu M., Kim H. C., Cass W. A., Sullivan P. G., Bing G., Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system Journal of Neurochemistry 2007 100 5 1375 1386
140. Xing B., Liu M., Bing G., Neuroprotection with pioglitazone against LPS insult on dopaminergic neurons may be associated with its inhibition of NF- B and JNK activation and suppression of COX-2 activity Journal of Neuroimmunology 2007 192 1-2 89 98 (Pubitemid 350213119)
141. Chung Y. C., Kim S. R., Jin B. K., Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease Journal of Immunology 2010 185 2 1230 1237
142. A. F. Thomas S., Wolf-Rdiger U., Christian H., Martin L., B. R. Raimund K., Manfrid E., Imidazopyridine derivatives useful as iNOS inhibitors. US7790710, 2010
143. T. J. Sharon N., Sam R., Guyan L., Yulin C., Jean M., Coumarins as iNOS inhibitors. US 7538233, 2009
144. M. O. Tadayoshi N., Yasuo K., Koji W., Takehito M., Sense Ologonucleotide capable of controlling the expression of iNOS and composition comprising the same. European Patent EP2031057, 2011
145. S.-J. K. Heonjoong N., O. Hyun-Sil K., Pharmaceutical composition,healthfood composition and iNOS inhibitors, containing Theopederin derivatives. WO/2008/072937A1, 2008
146. Singh I., Inhibitors of nitric oxide synthase. US20090192120, 2009